MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318560 | Name: Pravastatin Sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pravastatin Sodium is an antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells.

Chemical Structure

Pravastatin Sodium
Pravastatin Sodium
CAS#81131-70-6 (sodium)

Theoretical Analysis

MedKoo Cat#: 318560

Name: Pravastatin Sodium

CAS#: 81131-70-6 (sodium)

Chemical Formula: C23H35NaO7

Exact Mass: 0.0000

Molecular Weight: 446.52

Elemental Analysis: C, 61.87; H, 7.90; Na, 5.15; O, 25.08

Price and Availability

Size Price Availability Quantity
10mg USD 120.00
25mg USD 190.00
50mg USD 350.00
100mg USD 550.00
200mg USD 950.00
500mg USD 1,650.00
1g USD 2,650.00
2g USD 3,850.00
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
81131-70-6 (sodium) 85956-22-5 (lactone) 81093-37-0 (free acid)
Synonym
Pravastatin Sodium; Mevalotin; Elisor; Lipostat; Pravachol; Pravaselect; Apo-Pravastatin; Apotex Brand of Pravastatin Sodium; Aventis Brand of Pravastatin Sodium; Bristacol; Bristol-Myers Squibb Brand of Pravastatin Sodium; CS 514; CS-514; CS514; Elisor;
IUPAC/Chemical Name
sodium;(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
InChi Key
VWBQYTRBTXKKOG-IYNICTALSA-M
InChi Code
InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1
SMILES Code
CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
In vitro activity:
This study determined PRA (pravastatin) and SIM effects on vasorelaxation in aortic rings and NO production by cultured bovine aortic endothelial cells. Endothelium-dependent vasorelaxation was maximal with acetylocholine (ACH, 100%), followed by PRA (62.8%) and then SIM (37.1%). Direct measurement of NO confirmed that vasorelaxation is due to NO release and showed that PRA and ACH had similar dose-dependent effects on NO production, while SIM was only 25% to 30% as effective. Reference: J Am Coll Cardiol. 1999 Jan;33(1):234-41. https://pubmed.ncbi.nlm.nih.gov/9935036/
In vivo activity:
Pravastatin attenuated maternal hypertension, prevented placental weight loss, increased NO metabolites, inhibited increases in lipid peroxide levels, and reduced the activity of MMP-2, and these effects were observed along with enhanced endothelium-derived NO-dependent vasodilation. The present results provide evidence that pravastatin protects against activation of MMP-2 induced by oxidative stress in pre-eclamptic rats. Reference: Antioxidants (Basel). 2023 Apr 16;12(4):939. https://pubmed.ncbi.nlm.nih.gov/37107314/
Solvent mg/mL mM comments
Solubility
DMF 10.0 22.40
DMSO 60.9 136.42
Ethanol 45.8 102.46
PBS (pH 7.2) 10.0 22.40
Water 61.2 137.10
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 446.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Haydont V, Bourgier C, Pocard M, Lusinchi A, Aigueperse J, Mathé D, Bourhis J, Vozenin-Brotons MC. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5331-40. doi: 10.1158/1078-0432.CCR-07-0625. PMID: 17875761. 2. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999 Jan;33(1):234-41. doi: 10.1016/s0735-1097(98)00514-2. PMID: 9935036. 3. Toghi CJ, Martins LZ, Pacheco LL, Caetano ESP, Mattos BR, Rizzi E, Dias-Junior CA. Pravastatin Prevents Increases in Activity of Metalloproteinase-2 and Oxidative Stress, and Enhances Endothelium-Derived Nitric Oxide-Dependent Vasodilation in Gestational Hypertension. Antioxidants (Basel). 2023 Apr 16;12(4):939. doi: 10.3390/antiox12040939. PMID: 37107314; PMCID: PMC10135677. 4. Sato F, Wajima D, Takeshima Y, Nakagawa I, Kim T, Motoyama Y, Park YS, Nakase H. Neuroprotective effects of pravastatin in cerebral venous infarction in a rat model. IBRO Neurosci Rep. 2023 Feb 11;14:202-209. doi: 10.1016/j.ibneur.2023.02.002. PMID: 36852215; PMCID: PMC9958423.
In vitro protocol:
1. Haydont V, Bourgier C, Pocard M, Lusinchi A, Aigueperse J, Mathé D, Bourhis J, Vozenin-Brotons MC. Pravastatin Inhibits the Rho/CCN2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5331-40. doi: 10.1158/1078-0432.CCR-07-0625. PMID: 17875761. 2. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999 Jan;33(1):234-41. doi: 10.1016/s0735-1097(98)00514-2. PMID: 9935036.
In vivo protocol:
1. Toghi CJ, Martins LZ, Pacheco LL, Caetano ESP, Mattos BR, Rizzi E, Dias-Junior CA. Pravastatin Prevents Increases in Activity of Metalloproteinase-2 and Oxidative Stress, and Enhances Endothelium-Derived Nitric Oxide-Dependent Vasodilation in Gestational Hypertension. Antioxidants (Basel). 2023 Apr 16;12(4):939. doi: 10.3390/antiox12040939. PMID: 37107314; PMCID: PMC10135677. 2. Sato F, Wajima D, Takeshima Y, Nakagawa I, Kim T, Motoyama Y, Park YS, Nakase H. Neuroprotective effects of pravastatin in cerebral venous infarction in a rat model. IBRO Neurosci Rep. 2023 Feb 11;14:202-209. doi: 10.1016/j.ibneur.2023.02.002. PMID: 36852215; PMCID: PMC9958423.
1: Liu JH, Tian YY, Zhao XY, Li YL, Lyu YN, Liu C, Lin ZZ, Wang ZJ, Zuo ZP, Wang ZB. [Research on mechanism of hypolipidemic effect of Massa Medicata Fermentata based on metabolomics]. Zhongguo Zhong Yao Za Zhi. 2024 Feb;49(3):770-778. Chinese. doi: 10.19540/j.cnki.cjcmm.20231019.401. PMID: 38621881. 2: Logrippo S, Ganzetti R, Sestili M, Perinelli DR, Cespi M, Bonacucina G. Enteral Delivery of Pravastatin Sodium Tablets: Effect of Compounding into a Liquid Form and Co-Administration of Enteral Nutrition. Pharmacy (Basel). 2024 Feb 9;12(1):32. doi: 10.3390/pharmacy12010032. PMID: 38392939; PMCID: PMC10892702. 3: Elsayed SI, El-Dahan MS, Girgis GNS. Pharmacodynamic Studies of Pravastatin Sodium Nanoemulsion Loaded Transdermal Patch for Treatment of Hyperlipidemia. AAPS PharmSciTech. 2024 Feb 8;25(2):34. doi: 10.1208/s12249-024-02746-5. PMID: 38332233. 4: Mok CK, Ng YL, Ahidjo BA, Aw ZQ, Chen H, Wong YH, Lee RCH, Loe MWC, Liu J, Tan KS, Kaur P, Wang Y, Hao E, Hou X, Tan YW, Deng J, Chu JJH. Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants. Pharmaceutics. 2023 Mar 12;15(3):925. doi: 10.3390/pharmaceutics15030925. PMID: 36986786; PMCID: PMC10058714. 5: Maehara Y, Oki E, Ota M, Harimoto N, Ando K, Nakanishi R, Kawazoe T, Fujimoto Y, Nonaka K, Kitao H, Iimori M, Makino K, Takechi T, Sagara T, Miyadera K, Matsuoka K, Tsukihara H, Kataoka Y, Wakasa T, Ochiiwa H, Kamahori Y, Tokunaga E, Saeki H, Yoshizumi T, Kakeji Y, Shirabe K, Baba H, Shimada M. Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii. Int J Clin Oncol. 2023 May;28(5):613-624. doi: 10.1007/s10147-023-02326-w. Epub 2023 Mar 24. PMID: 36961615. 6: Sato F, Wajima D, Takeshima Y, Nakagawa I, Kim T, Motoyama Y, Park YS, Nakase H. Neuroprotective effects of pravastatin in cerebral venous infarction in a rat model. IBRO Neurosci Rep. 2023 Feb 11;14:202-209. doi: 10.1016/j.ibneur.2023.02.002. PMID: 36852215; PMCID: PMC9958423. 7: Elsayed SI, Girgis GNS, El-Dahan MS. Formulation and Evaluation of Pravastatin Sodium-Loaded PLGA Nanoparticles: In vitro-in vivo Studies Assessment. Int J Nanomedicine. 2023 Feb 13;18:721-742. doi: 10.2147/IJN.S394701. PMID: 36816332; PMCID: PMC9936887. 8: Pereira-da-Mota AF, Vivero-Lopez M, Garg P, Phan CM, Concheiro A, Jones L, Alvarez-Lorenzo C. In vitro-in vivo correlation of drug release profiles from medicated contact lenses using an in vitro eye blink model. Drug Deliv Transl Res. 2023 Apr;13(4):1116-1127. doi: 10.1007/s13346-022-01276-6. Epub 2022 Dec 17. PMID: 36528710; PMCID: PMC9981533. 9: Tu C, Lu H, Zhou T, Zhang W, Deng L, Cao W, Yang Z, Wang Z, Wu X, Ding J, Xu F, Gao C. Promoting the healing of infected diabetic wound by an anti-bacterial and nano-enzyme-containing hydrogel with inflammation-suppressing, ROS- scavenging, oxygen and nitric oxide-generating properties. Biomaterials. 2022 Jul;286:121597. doi: 10.1016/j.biomaterials.2022.121597. Epub 2022 May 22. PMID: 35688112. 10: Saraogi GK, Tholiya S, Mishra Y, Mishra V, Albutti A, Nayak P, Tambuwala MM. Formulation Development and Evaluation of Pravastatin-Loaded Nanogel for Hyperlipidemia Management. Gels. 2022 Jan 28;8(2):81. doi: 10.3390/gels8020081. PMID: 35200462; PMCID: PMC8871575. 11: Salem WA, Elkady EF, Fouad MA, Mohammad MA. DoE Screening and Optimization of Liquid Chromatographic Determination of Nicotinic Acid and Six Statins: Application to Pharmaceutical Preparations and Counterfeit Detection. J Chromatogr Sci. 2022 Dec 29;61(1):74-86. doi: 10.1093/chromsci/bmab131. PMID: 34894146. 12: Dai M, Chen Y, Mei X. Pravastatin sodium attenuated TREM-1-mediated inflammation in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2019 Jan 1;508(1):225-229. doi: 10.1016/j.bbrc.2018.11.098. Epub 2018 Nov 23. PMID: 30473214. 13: Homayun B, Sun C, Kumar A, Montemagno C, Choi HJ. Facile fabrication of microparticles with pH-responsive macropores for small intestine targeted drug formulation. Eur J Pharm Biopharm. 2018 Jul;128:316-326. doi: 10.1016/j.ejpb.2018.05.014. Epub 2018 May 16. PMID: 29753774; PMCID: PMC5998383. 14: Song H, Moon C, Lee BJ, Oh E. Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets. J Pharm Sci. 2018 Jul;107(7):1886-1895. doi: 10.1016/j.xphs.2018.03.003. Epub 2018 Mar 9. PMID: 29530714. 15: Lin CH, Hsu KW, Chen CH, Uang YS, Lin CJ. Differential changes in the pharmacokinetics of statins in collagen-induced arthritis rats. Biochem Pharmacol. 2017 Oct 15;142:216-228. doi: 10.1016/j.bcp.2017.06.118. Epub 2017 Jun 19. PMID: 28636885. 16: Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS; ALLHAT Collaborative Research Group. Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT- LLT Randomized Clinical Trial. JAMA Intern Med. 2017 Jul 1;177(7):955-965. doi: 10.1001/jamainternmed.2017.1442. PMID: 28531241; PMCID: PMC5543335. 17: Luo D, Kim JH, Park C, Oh E, Park JB, Cui JH, Cao QR, Lee BJ. Design of fixed dose combination and physicochemical characterization of enteric-coated bilayer tablet with circadian rhythmic variations containing telmisartan and pravastatin sodium. Int J Pharm. 2017 May 15;523(1):343-356. doi: 10.1016/j.ijpharm.2017.03.030. Epub 2017 Mar 19. PMID: 28330645. 18: Puttegowda VD, Karki R, Goli D, Jha SK, Mudagal MP. Formulation and Pharmacokinetic Evaluation of Microcapsules Containing Pravastatin Sodium Using Rats. Scientifica (Cairo). 2016;2016:7623193. doi: 10.1155/2016/7623193. Epub 2016 Aug 9. PMID: 27595040; PMCID: PMC4993944. 19: Bonacucina G, Logrippo S, Cespi M, Ganzetti R, Casettari L, Sestili M, Perinelli DR, Ricciutelli M, Marziali A, Polidori C, Palmieri GF. Chemical and microbiological stability studies of an aqueous solution of pravastatin sodium salt for drug therapy of the dysphagic patients. Eur J Hosp Pharm. 2016 Sep;23(5):288-293. doi: 10.1136/ejhpharm-2015-000781. Epub 2016 Feb 23. PMID: 31156867; PMCID: PMC6451617. 20: Dewland TA, Soliman EZ, Davis BR, Magnani JW, Yamal JM, Piller LB, Haywood LJ, Alonso A, Albert CM, Marcus GM; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Effect of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) on Conduction System Disease. JAMA Intern Med. 2016 Aug 1;176(8):1085-92. doi: 10.1001/jamainternmed.2016.2502. PMID: 27367818.